rheumatology
Rheumatoid arthritis

Upadacitinib PBS listing goes under the radar

The JAK inhibitor upadacitinib (Rinvoq) has been listed on PBS since 1 May for people with rheumatoid arthritis but its availability may have been overshadowed by the pandemic lockdown, a rheumatologist says. The once-daily JAK-1 selective inhibitor is now subsidised for treatment of adult patients with moderate to severe active RA who have responded inadequately ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic